Viewing Study NCT00209612



Ignite Creation Date: 2024-05-05 @ 11:59 AM
Last Modification Date: 2024-10-26 @ 9:18 AM
Study NCT ID: NCT00209612
Status: WITHDRAWN
Last Update Posted: 2009-02-17
First Post: 2005-09-13

Brief Title: Phase III Study of Paclitaxel Plus CPT-11 in Pts With 2nd Line Chemotherapy of Inoperable or Recurrent GC
Sponsor: Hokkaido Gastrointestinal Cancer Study Group
Organization: Hokkaido Gastrointestinal Cancer Study Group

Study Overview

Official Title: Phase III Study of Biweekly Administration Regimen of Paclitaxel Combined With CPT-11 in Patients With Second Line Chemotherapy of Inoperable or Recurrent Gastric CancerGC
Status: WITHDRAWN
Status Verified Date: 2009-02
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: due to strong side effect
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: A phase III study is conducted to determine the maximum-tolerated dose MTD dose-limiting toxicity DLT and efficacy of a combination chemotherapy using CPT-11 and Paclitaxel in pre-treated patients with metastatic gastric cancer The usefulness of the this regimen is evaluated by response rate median survival time and progression free survival
Detailed Description: Patients with pre-treated measurable metastatic gastric cancer were included in this trial Patients received this combination chemotherapy repeated every 28 days until progression disease Starting dose dose level 1 were CPT-11 80 mgm2 on day 1 and 15 Paclitaxel 60 mgm2 on day 1 and 15 DLT was defined as follows according to NCI-CTC version 20 Grade 4 neutropenia thrombocytopenia25000 Grade 3 neutropenia accompanied fever 38 and Grade 3 non-hematological toxicity except for nausea vomit appetite loss general fatigue alopecia Maximal Tolerated Dose MTD is determined when the incidence of critical toxicity exceeds 50 at a certain dose level Response rate will be calculated according to RECIST criteria

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
PacIri None None None